A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer
This study expands the understanding of the role of target therapy in improving survival of patients with mCRC based on real-world study results. These data represent potential survival outcomes of Taiwanese patients with mCRC in clinical practice. CRC is the most commonly diagnosed cancer and the t...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.808808/full |
| _version_ | 1818290214198575104 |
|---|---|
| author | Sheng-Chieh Huang Sheng-Chieh Huang Chun-Chi Lin Chun-Chi Lin Hao-Wei Teng Hao-Wei Teng Hung-Hsin Lin Hung-Hsin Lin Shih-Ching Chang Shih-Ching Chang Yuan-Tzu Lan Yuan-Tzu Lan Huann-Sheng Wang Huann-Sheng Wang Shung-Haur Yang Shung-Haur Yang Wei-Shone Chen Wei-Shone Chen Jeng-Kai Jiang Jeng-Kai Jiang |
| author_facet | Sheng-Chieh Huang Sheng-Chieh Huang Chun-Chi Lin Chun-Chi Lin Hao-Wei Teng Hao-Wei Teng Hung-Hsin Lin Hung-Hsin Lin Shih-Ching Chang Shih-Ching Chang Yuan-Tzu Lan Yuan-Tzu Lan Huann-Sheng Wang Huann-Sheng Wang Shung-Haur Yang Shung-Haur Yang Wei-Shone Chen Wei-Shone Chen Jeng-Kai Jiang Jeng-Kai Jiang |
| author_sort | Sheng-Chieh Huang |
| collection | DOAJ |
| description | This study expands the understanding of the role of target therapy in improving survival of patients with mCRC based on real-world study results. These data represent potential survival outcomes of Taiwanese patients with mCRC in clinical practice. CRC is the most commonly diagnosed cancer and the third leading cause of cancer-related death in Taiwan. The aim of this study was to evaluate the efficacy of target therapy in combination with chemotherapy for mCRC in Taiwan. This was a real-world, retrospective, observational study in patients diagnosed with mCRC (N=1583). A total of 792 patients received chemotherapy plus target therapy (anti-EGFR therapy, n=180; anti-VEGF therapy, n=612) and 791 patients who received chemotherapy alone. Overall survival (OS) and progression-free survival (PFS) were examined. For RAS wild-type patients, the median OS (mOS) was 34.3 months in the EGFR L (left-sided colon) group, 27.3 months in the VEGF L group, 18.4 months in VEGF R (right-sided colon) group, and 13.8 months in EGFR R group (P<0.001). Median PFS (mPFS) was 9.8 months in the EGFR L group, 8.9 months in the VEGF L group, 6.8 months in VEGF R group, and 5.8 months in EGFR R group. In patients with a RAS mutation, mOS was 25.4 months in the VEGF L group and 19.4 months in the VEGF R group (P=0.167). Judicious treatment allocation in Taiwanese patients with mCRC can result in an mOS of 34.3 months using cetuximab plus chemotherapy for left-sided tumors. An mOS of 48.5 months can be achieved using cetuximab plus chemotherapy in the neoadjuvant setting in mCRC patients with left-sided tumors. This study expands our understanding of the role of target therapy in improving survival of mCRC patients based on real-world study results. |
| first_indexed | 2024-12-13T02:24:37Z |
| format | Article |
| id | doaj.art-ee06e3c0334f40c7925839a4560ab0b4 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-13T02:24:37Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-ee06e3c0334f40c7925839a4560ab0b42022-12-22T00:02:41ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-03-011210.3389/fonc.2022.808808808808A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal CancerSheng-Chieh Huang0Sheng-Chieh Huang1Chun-Chi Lin2Chun-Chi Lin3Hao-Wei Teng4Hao-Wei Teng5Hung-Hsin Lin6Hung-Hsin Lin7Shih-Ching Chang8Shih-Ching Chang9Yuan-Tzu Lan10Yuan-Tzu Lan11Huann-Sheng Wang12Huann-Sheng Wang13Shung-Haur Yang14Shung-Haur Yang15Wei-Shone Chen16Wei-Shone Chen17Jeng-Kai Jiang18Jeng-Kai Jiang19Division of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, TaiwanSchool of Medicine, National Yang-Ming University, Taipei, TaiwanDivision of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, TaiwanSchool of Medicine, National Yang-Ming University, Taipei, TaiwanSchool of Medicine, National Yang-Ming University, Taipei, TaiwanDivision of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, TaiwanDivision of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, TaiwanSchool of Medicine, National Yang-Ming University, Taipei, TaiwanDivision of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, TaiwanSchool of Medicine, National Yang-Ming University, Taipei, TaiwanDivision of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, TaiwanSchool of Medicine, National Yang-Ming University, Taipei, TaiwanDivision of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, TaiwanSchool of Medicine, National Yang-Ming University, Taipei, TaiwanDivision of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, TaiwanSchool of Medicine, National Yang-Ming University, Taipei, TaiwanDivision of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, TaiwanSchool of Medicine, National Yang-Ming University, Taipei, TaiwanDivision of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, TaiwanSchool of Medicine, National Yang-Ming University, Taipei, TaiwanThis study expands the understanding of the role of target therapy in improving survival of patients with mCRC based on real-world study results. These data represent potential survival outcomes of Taiwanese patients with mCRC in clinical practice. CRC is the most commonly diagnosed cancer and the third leading cause of cancer-related death in Taiwan. The aim of this study was to evaluate the efficacy of target therapy in combination with chemotherapy for mCRC in Taiwan. This was a real-world, retrospective, observational study in patients diagnosed with mCRC (N=1583). A total of 792 patients received chemotherapy plus target therapy (anti-EGFR therapy, n=180; anti-VEGF therapy, n=612) and 791 patients who received chemotherapy alone. Overall survival (OS) and progression-free survival (PFS) were examined. For RAS wild-type patients, the median OS (mOS) was 34.3 months in the EGFR L (left-sided colon) group, 27.3 months in the VEGF L group, 18.4 months in VEGF R (right-sided colon) group, and 13.8 months in EGFR R group (P<0.001). Median PFS (mPFS) was 9.8 months in the EGFR L group, 8.9 months in the VEGF L group, 6.8 months in VEGF R group, and 5.8 months in EGFR R group. In patients with a RAS mutation, mOS was 25.4 months in the VEGF L group and 19.4 months in the VEGF R group (P=0.167). Judicious treatment allocation in Taiwanese patients with mCRC can result in an mOS of 34.3 months using cetuximab plus chemotherapy for left-sided tumors. An mOS of 48.5 months can be achieved using cetuximab plus chemotherapy in the neoadjuvant setting in mCRC patients with left-sided tumors. This study expands our understanding of the role of target therapy in improving survival of mCRC patients based on real-world study results.https://www.frontiersin.org/articles/10.3389/fonc.2022.808808/fullcolorectal cancermetastatic colorectal cancertarget therapycetuximabbevacizumabTaiwan |
| spellingShingle | Sheng-Chieh Huang Sheng-Chieh Huang Chun-Chi Lin Chun-Chi Lin Hao-Wei Teng Hao-Wei Teng Hung-Hsin Lin Hung-Hsin Lin Shih-Ching Chang Shih-Ching Chang Yuan-Tzu Lan Yuan-Tzu Lan Huann-Sheng Wang Huann-Sheng Wang Shung-Haur Yang Shung-Haur Yang Wei-Shone Chen Wei-Shone Chen Jeng-Kai Jiang Jeng-Kai Jiang A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer Frontiers in Oncology colorectal cancer metastatic colorectal cancer target therapy cetuximab bevacizumab Taiwan |
| title | A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer |
| title_full | A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer |
| title_fullStr | A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer |
| title_full_unstemmed | A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer |
| title_short | A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer |
| title_sort | long term and large scale real world study in taiwan efficacy of target therapy in stage iv colorectal cancer |
| topic | colorectal cancer metastatic colorectal cancer target therapy cetuximab bevacizumab Taiwan |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.808808/full |
| work_keys_str_mv | AT shengchiehhuang alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT shengchiehhuang alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT chunchilin alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT chunchilin alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT haoweiteng alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT haoweiteng alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT hunghsinlin alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT hunghsinlin alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT shihchingchang alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT shihchingchang alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT yuantzulan alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT yuantzulan alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT huannshengwang alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT huannshengwang alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT shunghauryang alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT shunghauryang alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT weishonechen alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT weishonechen alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT jengkaijiang alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT jengkaijiang alongtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT shengchiehhuang longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT shengchiehhuang longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT chunchilin longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT chunchilin longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT haoweiteng longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT haoweiteng longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT hunghsinlin longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT hunghsinlin longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT shihchingchang longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT shihchingchang longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT yuantzulan longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT yuantzulan longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT huannshengwang longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT huannshengwang longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT shunghauryang longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT shunghauryang longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT weishonechen longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT weishonechen longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT jengkaijiang longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer AT jengkaijiang longtermandlargescalerealworldstudyintaiwanefficacyoftargettherapyinstageivcolorectalcancer |